Forecast

The analysts' average price target is €15.85 (+331.88%). The median is €6.93 (+88.83%).

Buy	13
Hold	7
Sell	0

News Go to news feed

EyePoint: LUGANO misses primary endpoint, hope rests on pivotal LUCIA study

EyePoint reported that the phase‑III LUGANO trial for DURAVYU failed to meet the primary non‑inferiority endpoint in wet AMD, but highlighted strong secondary results and a favorable safety profile. Management attributed the failure to an unusually low rate of vision loss in the control arm and some non‑AMD‑related losses in the DURAVYU arm. DURAVYU showed a 42% reduction in treatment burden and high rates of no supplemental therapy; LUCIA (475 patients) will include a prespecified sensitivity analysis and is expected to deliver topline data in Q4 2024, with a positive outcome potentially supporting an FDA NDA. » More on de.investing.com
EyePoint: DURAVYU misses primary endpoint in LUGANO, approval path remains open

EyePoint reports that DURAVYU missed the noninferiority endpoint in the Phase III LUGANO study for wet AMD; management attributes the result to an unusually low event rate in the control arm. Secondary endpoints, however, showed strong results for safety, anatomical control and a 42% reduction in treatment burden, so the company is hopeful for a positive outcome from the second study, LUCIA. EyePoint has about $180m in cash, which management says should fund operations through Q4 2027; results from the DME studies COMO and CAPRI are expected in Q4 2025. » More on de.investing.com
EyePoint: DURAVYU misses primary endpoint in Phase‑3 study for wet AMD

The Phase‑3 LUGANO study of DURAVYU did not meet the primary endpoint of change in best‑corrected visual acuity versus aflibercept in the full dataset. After excluding an asymmetric cohort of nine patients, an ad‑hoc analysis showed nominal non‑inferiority (p=0.0096). Key secondary endpoints were met: DURAVYU reduced treatment burden by 42% (on average two fewer injections through week 56) and many patients remained without additional treatment for weeks; safety data showed no relevant differences versus the control group. EyePoint expects LUCIA topline data in Q4 2026 and, depending on those results, aims for an FDA filing in H1 2027. » More on de.investing.com

Financials

In the last quarter, EyePoint Pharmaceuticals had revenue of €444.24k and net profit of -€82.78m

(EUR)	June 2026	YoY
Revenue	444.24k	90.18%
Gross profit	444.24k	89.87%
Net profit	-82.78m	64.18%
EBITDA	-81.61m	63.61%

Fundamentals

Metric	Value
Market capitalization	€307.41m
Number of shares	83.84m
52-week high/low	€16.56 - €3.42
Dividends	No
Beta	1.64
P/E ratio	-1.13
PEG ratio	0.04
P/B ratio	2.20
P/S ratio	127.16

Company profile

EyePoint Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen, das ophthalmologische Produkte für die Behandlung von Augenkrankheiten in den Vereinigten Staaten, China und Großbritannien entwickelt und vertreibt. Das Unternehmen bietet ILUVIEN, ein injizierbares Mikro-Insert mit verzögerter Wirkstofffreisetzung zur Behandlung des diabetischen Makulaödems, YUTIQ, ein Fluocinolonacetonid-Implantat zur intravitrealen Injektion für die Behandlung chronischer, nicht-infektiöser Uveitis, die das hintere Augensegment betrifft, und DEXYCU, eine Dexamethason-Suspension für das Auge, zur Behandlung postoperativer Augenentzündungen, einschließlich der Behandlung nach Kataraktoperationen. Darüber hinaus entwickelt das Unternehmen EYP-1901, eine zweimal jährlich bioerodierbare Formulierung eines Tyrosinkinase-Hemmers zur Behandlung der feuchten altersbedingten Makuladegeneration, der diabetischen Retinopathie und des Netzhautvenenverschlusses, sowie YUTIQ50 zur Behandlung der chronischen, nicht-infektiösen Uveitis, die den hinteren Teil des Auges betrifft. Das Unternehmen unterhält strategische Kooperationen mit Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics und Equinox Science, LLC. Darüber hinaus besteht eine kommerzielle Allianz mit ImprimisRx PA, Inc. zur gemeinsamen Vermarktung von DEXYCU zur Behandlung von postoperativen Entzündungen nach Augenoperationen. Das Unternehmen war früher als pSivida Corp. bekannt und änderte im März 2018 seinen Namen in EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. wurde 1987 gegründet und hat seinen Hauptsitz in Watertown, Massachusetts.

Name	EyePoint Pharmaceuticals
CEO	Jay S. Duker
Headquarters	Watertown, ma USA
Website	eyepointpharma.com
Industry	Health Care Equipment & Supplies
IPO	27/01/2005
Employees	214